SCHEMBL1193340

SCHEMBL1193340

O=C(CCCCBr)Nc1ccc2ccccc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.74
LMNA P02545 3/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
NPC1 O15118 2/20 0.74
CYP1A2 P05177 2/20 0.66
HDAC1 Q13547 6/20 0.65
HDAC2 Q92769 3/20 0.65
MAPT P10636 5/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
HDAC3 O15379 3/20 0.62
HDAC6 Q9UBN7 3/20 0.62
HDAC8 Q9BY41 3/20 0.62
HDAC4 P56524 2/20 0.62
HDAC7 Q8WUI4 2/20 0.62
HDAC10 Q969S8 2/20 0.62
HDAC11 Q96DB2 2/20 0.62
HDAC9 Q9UKV0 2/20 0.62
HDAC5 Q9UQL6 2/20 0.62
POLB P06746 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12658954 0.85 NPC1 (0.74) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL7203505 0.85 RAB9A (1.00) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL12672516 0.85 NPC1 (0.74) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL1232359 0.84 RAB9A (0.72) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL30445477 0.84 RAB9A (0.76) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL28931481 0.83 RAB9A (0.91) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL29286771 0.82 MAPT (0.72) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL1233158 0.81 RAB9A (0.71) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL1613715 0.81 HDAC1 (0.68) RAB9ASMN1; SMN2NPC1CYP1A2HDAC1
SCHEMBL3096584 0.81 CYP1A2 (0.73) RAB9ALMNASMN1; SMN2NPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2220060-B1 TETRAHYDROBENZOTHIAZOLE DERIVATIVES MOTAC NEUROSCIENCE LTD (GB) 2016-09-14 EP disclosed
US-8389555-B2 Medicaments MOTAC NEUROSCIENCE LIMITED (GB) 2013-03-05 US disclosed
US-20110046153-A1 Medicaments MOTAC NEUROSCIENCE LIMITED (GB) 2011-02-24 US disclosed
EP-2220060-A1 MEDICAMENTS Motac Neuroscience Limited (GB) 2010-08-25 EP disclosed
WO-2009056805-A1 MEDICAMENTS MOTAC NEUROSCIENCE LIMITED (GB) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046153-A1 Medicaments MTNR1A, SIGMAR1, OPRK1 RAB9A 3425/4885LMNA 3969/4885SMN1; SMN2 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.